Alzhmerat
250 mg/ml, 4 ml № 5
Pharmacotherapeutic group
Active ingredient
Pharmaceutical form
Solution for injections
ATC code
N07AX02
RX/OTC
RX
Registration certificate
UA/15056/01/01
General properties
Pharmacotherapeutic group
Medications that affect the nervous system. Parasympathomimetics. Choline alfoscerat.
Therapeutic indications
- The acute period of severe traumatic brain injury with a predominantly stem level of damage (impaired consciousness, coma, focal hemispheric symptoms, symptoms of damage to the brain stem).
- Degenerative-involutionary brain psychoorganic syndromes or secondary consequences of cerebrovascular insufficiency, that is, primary and secondary mental disorders in the elderly, which are characterized by impaired memory, confusion, disorientation, reduced motivation and initiative, reduced ability to concentrate; changes in the emotional sphere and sphere of behavior: emotional instability, irritability, indifference to the environment; pseudomelancholy in the elderly.
Contraindications
Hypersensitivity to the drug or its components.
During pregnancy and breastfeeding.
Psychotic syndrome, with severe psychomotor agitation.
Pharmaceutical characteristics
Main physicochemical properties
Colorless or yellowish clear liquid.
Shelf life
3 years.
Storage
Store in original packaging at a temperature not higher than 25 °C.
Keep out of the reach of children.
Manufacturer
PJSC "Lekhim-Kharkiv".
Location
36, Severyna Pototskoho St., 61115 Kharkiv, Ukraine.
